Orasis Revenue and Competitors
Estimated Revenue & Valuation
- Orasis's estimated annual revenue is currently $6.6M per year.
- Orasis's estimated revenue per employee is $201,000
Employee Data
- Orasis has 33 Employees.
- Orasis grew their employee count by 6% last year.
Orasis's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Sr. VP, Head Strategy & Marketing | Reveal Email/Phone |
2 | VP Medical Affairs | Reveal Email/Phone |
3 | VP Finance | Reveal Email/Phone |
4 | CMC Associated Director | Reveal Email/Phone |
5 | President and Chief Operating Officer | Reveal Email/Phone |
6 | Director, US Clinical Operations | Reveal Email/Phone |
7 | Associate Director Clinical Operations | Reveal Email/Phone |
8 | Director QA | Reveal Email/Phone |
9 | Associate Director CMC | Reveal Email/Phone |
Orasis Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $46.2M | 230 | 5% | N/A | N/A |
#2 | $43.8M | 218 | 21% | N/A | N/A |
#3 | $57.1M | 284 | 26% | N/A | N/A |
#4 | $24.5M | 122 | 3% | N/A | N/A |
#5 | $52.9M | 263 | 13% | N/A | N/A |
#6 | $24.7M | 123 | 13% | N/A | N/A |
#7 | $1.8M | 18 | 0% | $114.3M | N/A |
#8 | $7.2M | 36 | -20% | N/A | N/A |
#9 | $13.7M | 68 | -7% | N/A | N/A |
#10 | $7.6M | 39 | -13% | $123.9M | N/A |
What Is Orasis?
Orasis is an emerging ophthalmic pharmaceutical company with the goal of making near vision clear again. We are committed to the Ophthalmology and Optometry segments because we know that presbyopia is ubiquitous. By virtue of our first in class formulation, Orasis is well positioned to be first line therapy in this emerging category by addressing a significant unmet need for patients.
keywords:N/A
N/A
Total Funding
33
Number of Employees
$6.6M
Revenue (est)
6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Orasis News
Orasis Pharmaceuticals announced that its phase 3 trials showed patients treated with CSF-1 achieved a statistically significant three-line...
Orasis Pharmaceuticals Announces Positive Phase 3 Topline Results of Novel Eye Drop Candidate, CSF-1, for the Treatment of Presbyopia.
Orasis Pharmaceuticals announced that its eye drop candidate CSF-1 met all primary and key secondary endpoints in Phase III clinical trials.